ArticleJournal of thoracic disease2025
The efficacy and adverse reactions of minocycline against
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Clinical value of neutrophil-to-lymphocyte ratio and D-dimer in predicting the efficacy of minocycline for pediatric Mycoplasma pneumoniae pneumonia.Frontiers in pediatrics · 2026Article
- Immune activation and mucin dysregulation in pediatric refractoryFrontiers in cellular and infection microbiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Methods: A comprehensive search was conducted in PubMed, Web of Science, China National Knowledge Infrastructure (CNKI), and Wanfang Database up to March 2024. The control groups in these trials primarily received azithromycin (10 mg/kg/d) as a standard treatment. RCTs on minocycline treatment for MPP were included and analyzed using RevMan 5.4 software. Results: Thirteen RCTs involving 325 participants, including 48 in self-control trials, were included. The overall treatment efficacy of the minocycline treatment group was significantly higher than that of the control group [odds ratio (OR) =2.24; 95% confidence interval (CI): 1.31-3.84; P=0.003]. Hospitalization duration was significantly shorter in the minocycline group [mean difference (MD) =7.57; 95% CI: 6.96-8.19; P<0.001]. The duration of fever (MD =5.90; 95% CI: 4.82-6.97; P<0.001) and cough resolution time (MD =3.15; 95% CI: 2.58-3.72; P<0.001) were also significantly reduced. The rate of adverse reactions was significantly lower in the minocycline group (OR =0.51; 95% CI: 0.35-0.74; P<0.001). Conclusions: This meta-analysis reveals that minocycline significantly enhances treatment efficacy for refractory MPP, promotes recovery, and merits broader clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.